Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

Haematologica. 2015 Dec;100(12):e494-5. doi: 10.3324/haematol.2015.132845. Epub 2015 Sep 4.
No abstract available

Keywords: chronic myeloid leukemia; phase II; ponatinib; resistant; tyrosine kinase inhibitor.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Drug Resistance, Neoplasm / drug effects*
  • Female
  • Humans
  • Imidazoles / administration & dosage*
  • Imidazoles / adverse effects
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / adverse effects
  • Pyridazines / administration & dosage*
  • Pyridazines / adverse effects

Substances

  • Imidazoles
  • Protein Kinase Inhibitors
  • Pyridazines
  • ponatinib